Literature DB >> 1472033

Generation of specificity-variant antibodies by alteration of carbohydrate in light chain of human monoclonal antibodies.

H Tachibana1, S Shirahata, H Murakami.   

Abstract

A hybridoma line, C5TN, produced human monoclonal antibody of which light chain had N-linked carbohydrate chain within the variable region. Some molecular-weight variants of light chain of the antibody were produced by C5TN variants resistant to cytotoxic effect of concanavalin A. The variant antibodies significantly altered the original cross-reactivity with antigens or lost the ability of antigen binding. The variants variously trimmed their carbohydrate chains by glycosidases, showed the changed reactivity or acquired the ability to bind for antigens. The carbohydrate-deficient antibodies from tunicamycin-treated C5TN and the variant clones behaved in a similar manner on antigen-binding reactivity. Furthermore, comparison of antibodies of which light chains have carbohydrate chains sensitive and resistant to some glycosidases showed that carbohydrate chain in variable region of light chain can influence their reactivity with antigen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1472033     DOI: 10.1016/0006-291x(92)92246-t

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Polyunsaturated fatty acids are not essential for survival and proliferation of a human B cell line.

Authors:  Y Miyazaki; M Noguchi; H Tachibana; K Yamada
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Jul-Aug       Impact factor: 2.416

2.  Building high affinity human antibodies by altering the glycosylation on the light chain variable region in N-acetylglucosamine-supplemented hybridoma cultures.

Authors:  H Tachibana; J Y Kim; S Shirahata
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

3.  Divergent members of a single autoreactive B cell clone retain specificity for apoptotic blebs.

Authors:  Indira Neeli; Mekel M Richardson; Salar N Khan; Danielle Nicolo; Marc Monestier; Marko Z Radic
Journal:  Mol Immunol       Date:  2006-11-03       Impact factor: 4.407

4.  Modified antigen-binding of human antibodies with glycosylation variations of the light chains produced in sugar-limited human hybridoma cultures.

Authors:  H Tachibana; K Jiyoun; K Taniguchi; Y Ushio; K Teruya; K Osada; Y Inoue; S Shirahata; H Murakami
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-03       Impact factor: 2.416

5.  Glycosylation of antibody in a lectin-resistant human hybridoma is insensitive to glucose.

Authors:  H Tachibana; Y Ushio; H Murakami
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-04       Impact factor: 2.416

6.  Hybridoma growth in a new generation hollow fibre bioreactor: antibody productivity and consistency.

Authors:  N Kessler; G Thomas; L Gerentes; G Delfosse; M Aymard
Journal:  Cytotechnology       Date:  1997-07       Impact factor: 2.058

7.  Changes of monosaccharide availability of human hybridoma lead to alteration of biological properties of human monoclonal antibody.

Authors:  H Tachibana; K Taniguchi; Y Ushio; K Teruya; K Osada; H Murakami
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

8.  An Approach to Further Enhance the Cellular Productivity of Exogenous Protein Hyper-producing Chinese Hamster Ovary (CHO) Cells.

Authors:  Kiichiro Teruya; Yoshihito Daimon; Xiao-Yan Dong; Yoshinori Katakura; Takumi Miura; Akira Ichikawa; Tsukasa Fujiki; Makiko Yamashita; Tetsuya Mori; Hideya Ohashi; Sanetaka Shirahata
Journal:  Cytotechnology       Date:  2005-01       Impact factor: 2.058

9.  Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies.

Authors:  Peng-Cheng Xu; Shen-Ju Gou; Xiao-Wei Yang; Zhao Cui; Xiao-Yu Jia; Min Chen; Ming-Hui Zhao
Journal:  BMC Immunol       Date:  2012-03-09       Impact factor: 3.615

Review 10.  Production of monoclonal antibodies in plants for cancer immunotherapy.

Authors:  Ghislain Moussavou; Kisung Ko; Jeong-Hwan Lee; Young-Kug Choo
Journal:  Biomed Res Int       Date:  2015-10-15       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.